Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Greg Critchfield
AddedMar 31, 2024
UpdatedMay 31, 2026
Greg Critchfield

Greg Critchfield

Board Member, Sera Prognostics

CrunchbaseLinkedIn

Greg Critchfield's Career

Sera Prognostics
Sera Prognostics

Salt Lake City, UT, US

Board Member· Board
Metamark Genetics
Metamark Genetics

Cambridge, MA, US

Board Member· Board
Nodality
Nodality

South San Francisco, CA, US

Board Member· Board
Epic Sciences
Epic Sciences

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Greg Critchfield's Career

Sera Prognostics
Sera Prognostics
Public$245.6M1132008Salt Lake City, UT, US
Board Member· Board

Leadership at Sera Prognostics

Evguenia LindgardtEvguenia LindgardtCEO
Kim KamdarKim KamdarBoard Member
Jane F. BarlowJane F. BarlowBoard Member
Steve BorstSteve BorstCo-Founder
Arnie OronskyArnie OronskyBoard Member
Dennis FarrarDennis FarrarBoard Member
Metamark Genetics
Metamark Genetics
Acquired$37.6M02007Cambridge, MA, US
Board Member· Board

Leadership at Metamark Genetics

Kenneth E. WegKenneth E. WegBoard Member
Michael KauffmanMichael KauffmanBoard Member
Lynda ChinLynda ChinCo-Founder
Ronald DepinhoRonald DepinhoCo-Founder
David RimmDavid RimmCo-Founder
Raju KucherlapatiRaju KucherlapatiBoard Member
Nodality
Nodality
Series B$62M752003South San Francisco, CA, US
Board Member· Board

Leadership at Nodality

Garry NolanGarry NolanBoard Member
Michael GoldbergMichael GoldbergBoard Member
Omar PerezOmar PerezFounder
Laura BregeLaura BregeCEO
David SingerDavid SingerBoard Member
Andrew R. AllenAndrew R. AllenBoard Member

Similar to Nodality

NormunityNormunityWest Haven, CT, USCancer Treatmentsest. 2021NormunityWest Haven, CT, US · est. 2021

Normunity: A biotech firm innovating precision immuno-oncology medicines to boost body's cancer immunity.

Series A · $65M15
Nuon TherapeuticsNuon TherapeuticsSan Mateo, CA, USTherapiesest. 2002Nuon TherapeuticsSan Mateo, CA, US · est. 2002

Nuon Therapeutics: A US-based biotech firm innovating therapies for autoimmune and inflammatory diseases.

Series A · $48M75
NantkwestNantkwestCulver City, CA, USCancer Treatment, Immunotherapyest. 2014NantkwestCulver City, CA, US · est. 2014

ImmunityBio, Inc.: A US-based biotech firm specializing in immunotherapy for cancer and infectious diseases.

Public · $103.5M51
NantBioNantBioCulver City, CA, USPharmaceuticalsNantBioCulver City, CA, US

NantBioscience: LA-based developer of targeted pharmaceuticals for cancer treatment.

Late Stage Private · $180.1M75
Epic Sciences
Epic Sciences
Series G$219.5M1142008San Diego, CA, US
Board Member· Board

Leadership at Epic Sciences

Evgeny ZaytsevEvgeny ZaytsevBoard Member
Richard EglenRichard EglenBoard Member
James RothmanJames RothmanBoard Member
Murali PrahaladMurali PrahaladBoard Member
Peter KuhnPeter KuhnFounder
Andrew ElbardissiAndrew ElbardissiBoard Member

Similar to Epic Sciences

Epi OneEpi OneNew York City, NY, USCancer Diagnosticsest. 2016Epi OneNew York City, NY, US · est. 2016

Revolutionary cancer diagnosis platform for early prognosis, detection, and drug response.

Series B · $22.9M36
EpinomaEpinomaSan Francisco, CA, USCancer Diagnosticsest. 2020EpinomaSan Francisco, CA, US · est. 2020

Innovative diagnostics company using multi-omics for cancer monitoring. Founded in 2020, based in San Francisco.

Pre-Seed · $125k6
OnCirc DiagnosticsOnCirc DiagnosticsBeverly Hills, CA, USCancer Diagnosticsest. 2009OnCirc DiagnosticsBeverly Hills, CA, US · est. 2009

Innovative cancer diagnostics biotech in Beverly Hills.

Pre-Seed · $500k30
Exact SciencesExact SciencesMadison, WI, USCancer Diagnosticsest. 1995Exact SciencesMadison, WI, US · est. 1995

Exact Sciences Corp., a US-based firm, develops non-invasive tests for early colorectal cancer detection.

Public · $2.1B6.4k

Greg Critchfield's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Greg Critchfield

Eric DahlhauserEric DahlhauserBoard Member · Insight GeneticsKrishna jayaramanKrishna jayaramanBoard Member · Genomics USAKevin ConroyKevin ConroyBoard Member · Exact SciencesWalker LongWalker LongCEO · GeneBiologyDrew SpaventaDrew SpaventaCo-Founder · Axon VenturesVic AhmedVic AhmedBoard Member · Playpal